Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"BRAF V600E"”.
-
Roles For Braf Kinase Activating Mutations In Melanoma: Microenvironmental Immunosuppression
<p>The BRAF oncogene demonstrates a characteristic mutation (V600E) in a significant fraction of cutaneous melanomas, leading to constitutive activation of the MAP kinase pathway. This genetic lesion endows tumor cells with proliferative and survival advantages, and metastatic melanoma patients …
-
Epigenetic Modulation In Braf Mutated Metastatic Colorectal Cancer
<p><strong>Introduction:</strong> BRAF V600E mutations are associated with poor clinical outcomes for patients with metastatic colorectal cancer (mCRC). Unlike other tumors with the same mutation, BRAF inhibitors are ineffective as monotherapy. CRC tumors with BRAF V600E mutations are associated …
-
Investigation of key non-coding and coding genes in cutaneous melanomagenesis
… The second biomarker investigated, mutated BRAF, has been seen in 50-70% of spontaneous cutaneous melanoma. The commonest mutation in melanoma is a glutamic acid for valine substitution at position 600 (V600E). Oncogenic BRAF controls many aspects of melanoma cell biology. The aim of this …
-
Differentiating follicular thyroid carcinoma from the follicular variant of papillary thyroid carcinoma
… expression of biomarkers HBME-1, CD15, CK-19 and BRAF V600E in follicular adenoma, follicular carcinoma and follicular variant of papillary thyroid carcinoma. To ascertain the usefulness of these markers in differentiating these follicular-patterned thyroid neoplasms. Materials and methods: This …
-
Investigation of signalling pathways associated with the development of BRAF inhibitor resistance and treatment of melanoma
… It is the fifth most common cancer in UK. BRAF V600E mutation is observed in approximately 50% of melanomas and causes excessive stimulation of the MAPK signalling leading to proliferation, metastasis and invasion. In BRAF V600E positive mela-noma patients, BRAF is inhibited to prevent MAPK …
-
Investigating the Role of Complex I Loss in Thyroid Tumorigenesis
… thyroid cancer, driven universally by the BRAF V600E activating mutation. I have developed a murine model of Braf-driven thyroid cancer to investigate the role of Complex I loss in both tumor initiation and progression.
-
A NOVEL BRAF SIGNALING CASCADE THROUGH p-21 ACTIVATED KINASES REGULATES THYROID CANCER CELL MOTILITY
… is the presence of the activating mutation BRAF V600E. From our prior studies, we determined that the invasive fronts of aggressive PTC exhibited a characteristic change in morphology known as epithelial-to-mesenchymal transition (EMT). EMT has been linked to aggressive or late stage tumor …
-
CRISPR-integrated Biosensors for Human Health: Novel strategies for pathogen detection and cancer screening
… amplification enabled sensitive detection of the BRAF V600E mutation in colorectal cancer cells. Fourth, a one-pot CRISPR/Cas13 biosensor was designed for simultaneous detection of E. coli O157:H7 serotype markers, validated in a mouse infection model. Finally, the sensitivity of the CRISPR/Cas12a …
-
Σύγχρονα δεδομένα για τη διάγνωση και θεραπεία της ιστιοκύττωσης Langerhans / Current concepts for the diagnosis and management of Langerhans cell histiocytosis
… ενεργοποιητικών μεταλλάξεων, κυρίως της BRAF V600E και του MAP2K1. Τα δεδομένα αυτά επιβεβαίωσαν τον νεοπλασματικό χαρακτήρα της νόσου και συνέβαλαν στην ανάπτυξη στοχευμένων θεραπευτικών επιλογών. Η διάγνωση της LCH βασίζεται σε συνδυασμό κλινικών, απεικονιστικών, ιστολογικών και …
-
The Temporal and Contextual Relationship of NRF2 Activation and Cancer
… in relation to the dark side of NRF2, in BRAF V600E mutant melanoma, cellular localization changes of FAM129B facilitates its binding with KEAP1, which in turn induced NRF2 and increased metastatic potential. Further work in arsenic-transformed bronchial cells and NSCLC revealed that NRF2 …
-
Nucleic acid sample preparation using magnetic ionic liquids as cell lysis and DNA extraction solvents
… urine. With the ITO-MIL extraction, 0.1% BRAF V600E (99.9% wild-type BRAF) could be discriminated from a 100% wild-type BRAF standard. In comparison, without the sequence-specific extraction, the 9% BRAF V600E could not be differentiated from the 100% wild-type BRAF standard. Commercial …
-
The pathological and genomic impact of CTCF depletion in mammalian model systems
… DEN exposure was characterised, revealing that Braf(V637E), orthologous to BRAF(V600E) in humans, was the predominant oncogenic driver in these liver tumours. Taken together, while Ctcf loss is partially physiologically compensated, chronic CTCF depletion dysregulates gene expression by subtly …
-
Investigating the clinicopathological spectrum and associated genetics of colorectal carcinoma in young (<60 years of age) patients in the Western Cape Province
… frequency than described in the literature. BRAF V600E mutations were absent. Although there were differences in the frequencies of mutations in the major driver genes, the frequencies of oncogenic pathway alterations were similar. FAT4 (26%) and TET2 (15%) have emerged as important novel …
-
Clinico-morphological Characteristics, Histological Typification and Their Correlation with Some Molecular Markers in Cutaneous Melanoma // Клинико-морфологични характеристики, хистотипизация и корелацията им с някои молекулярни маркери при кожен меланом
… при кожен меланом. Предиктивността на анти-BRAF антитяло спрямо туморната биология на кожния меланом е съществена. Поради този факт вариантът за предшестващо молекулярната детекция имунохистохимично тестване е финансово изгодна и ефективна опция, особено при лезии с ниско туморно съдържание …
-
Deficiência de arginina-vasopressina (diabetes insipidus central) como primeira manifestação de histiocitose de células de Langerhans: relato de caso
… mutations in the MAPK/ERK pathway (such as BRAF V600E and MAP2K1). Involvement of the hypothalamic–pituitary axis occurs in up to 30% of cases, presenting as arginine-vasopressin (AVP) deficiency—classically known as central diabetes insipidus (CDI)—often with panhypopituitarism. In adults, …
-
Modeling of Cns Cancer With A Focus On The Immune Component
… Sixty-seven percent of patients had the <em>BRAF V600E</em> missense mutation, frequent in the papillary craniopharyngioma subtype. One patient had a missense mutation in the WNT pathway, specifically a mutation in <em>CTNNB1</em> associated with the adamantinomatous subtype. …